Hosted by Unknown Host · 🇺🇸 US · EN · 196 episodes
Established thought leaders with verified media credentials.
On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.
Unknown Host hosts On The Pen GLP-1 News, a health show with 196 episodes published.
Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode of On The Pen, Dave K
ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) to break down the molecules, clinical trials, weight los
Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference. Together, they expl
Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.
Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel Skowronski, who sugg
https://linktr.ee/manonthemounjaro
This episode examines a serious case involving retatrutide, where an individual experienced an overdose due to improper medication administration. We discuss the critical importance of medication safety and patient safet
We just got done listening to the quarter one, 2026 Eli Lilly earnings call. There was a lot of information to get into, whether you're interested in retatrutide, eloralintide, or Foundayo, and all of the numbers that we
https://www.otplinks.com A new GLP-1 and glucagon agonist dropped data that was supposed to rival retatrutide, just without the GIP, and on the surface the results look solid. But that is not the real story. Even when pe
Major disruption hits the GLP-1 landscape as another large 503B compounding pharmacy halts production of semaglutide and tirzepatide. In this episode, we unpack what’s driving the FDA’s increased enforcement and why thes
ON THE PEN RESOURCES AND LINKS: HTTPS://WWW.OTPLINKS.COM What if the most powerful obesity drug ever created ends up being the one you can’t get? That’s the real conversation around retatrutide right now. In this video,
This conversation dives headfirst into one of the most controversial and least understood side effects of GLP-1 medications, what many are now calling the “Ozempic personality.” In this candid interview, Dr. Spencer Nado
Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require refrigeration and i
If you just look at the headlines, things look great for access to GLP-1 medications but for some of those already using these medications things are changing and getting tighter. Listen in as Dave breaks down the news o
Are you on tirzepatide or semaglutide and struggled with inconsistent weight loss and side effects? On this episode of On The Pen, Dave Knapp and Dr. Ian Ellis dive into the surprising variability of GLP-1 dosing (retatr
A major shift in obesity treatment is underway following a surprising pricing move that could change how patients access care. This episode explores the growing divide between traditional healthcare and alternative pathw
Access to compounded and research-grade GLP-1s may be tightening, as comments from Robert F. Kennedy Jr. signal increased enforcement and a push back toward branded medications. At the same time, new data on retatrutide
Detected from recent episode content. Sponsor presence is a real signal of listener purchasing power and show monetisation.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch On The Pen GLP-1 News, visit http://OTPlinks.com for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent health coverage.
On The Pen GLP-1 News is hosted by Unknown Host. The show is categorised under Health (fitness) and has published 196 episodes.
On The Pen GLP-1 News has published 196 episodes.
On The Pen GLP-1 News regularly covers Health, Fitness, Medicine. It sits in the Health category, with a fitness focus.
On The Pen GLP-1 News is accessible for guests with genuine health expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
On The Pen GLP-1 News hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of On The Pen GLP-1 News average 36 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates On The Pen GLP-1 News's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 13 days ago.
